SC5b-9 antibody | 056B-18.104.22.168 (3R2/0)
Filter by Application:E Reset
Mouse anti Human SC5b-9
- Product Type
- Monoclonal Antibody
- 056B-22.214.171.124 (3R2/0)
|Mouse anti Human SC5b-9 antibody, clone 056B-126.96.36.199 (3R2/0) recognizes the SC5b-9 complex of around 330 kDa. Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation.
Removal of Sodium Azide is recommended prior to use in functional assays.
Mouse anti Human SC5b-9 antibody, clone 3R2/0 has been reported to work in western blotting applications.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from ascites
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Approx. Protein Concentrations
- Current, batch-specific concentration 1.18 mg/ml
- For research purposes only
- Guaranteed for 12 months from the date of despatch or until the date of expiry, whichever comes first. Please see label for expiry date.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
- Histology Positive Control Tissue
- Kidney from post streptoccal glomerulonephritis patients.
References for SC5b-9 antibody
Baksmeier, C. et al. (2021) Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination.
Immunology. 164 (1): 90-105.
Biesecker, G. (1990) The complement SC5b-9 complex mediates cell adhesion through a vitronectin receptor.
J Immunol. 145 (1): 209-14.
Greenstein, J.D. et al. (1995) The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.
Clin Exp Immunol. 100 (1): 40-6.
Rus, H. et al. (2005) C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
Ann Med. 37 (2): 97-104.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up